BACKGROUND: Tenascin-C is an extracellular matrix protein known to correlate with prognosis in patients with glioblastoma, probably by stimulation of invasion and neoangiogenesis. Transforming Growth Factor-beta1 (TGF-beta1) plays an important role in the biology of high-grade gliomas, partly by regulating invasion of these tumors into parenchyma. This study was designed to evaluate if TGF-beta1 induces the expression and deposition of Tenascin-C in the extracellular matrix of high-grade gliomas which may be pivotal for the invasion of these tumors into healthy parenchyma. METHODS: A series of 20 high-grade gliomas was stained immunohistochemically with Tenascin-C- and TGF-beta1- specific antibodies. Expression levels of both proteins were evaluated and correlated with each other, time to progression and molecular and morphological markers of invasion. A quantitative PCR assay was performed evaluating the induction of Tenascin-C mRNA by treatment with TGF-beta1 in vitro. RESULTS: Tenascin-C was expressed in 18 of 19 (95%) evaluable tumors, whereas 14 of 20 tumors (70%) expressed TGF-beta1 in a significant percentage of cells. Treatment with TGF-beta1 did induce the expression of Tenascin-C at the mRNA and protein level in vitro. The expression of Tenascin-C and TGF-beta1 did neighter statistically correlate with each other nor with time to progression. CONCLUSION: In our series, Tenascin-C and TGF-beta1 were expressed in the vast majority of high-grade gliomas. We could not detect a correlation of one of the proteins with time to progression. Nevertheless, we describe induction of Tenascin-C by TGF-beta1, possibly providing a mechanism for the invasion of high-grade gliomas into healthy parenchyma.
BACKGROUND:Tenascin-C is an extracellular matrix protein known to correlate with prognosis in patients with glioblastoma, probably by stimulation of invasion and neoangiogenesis. Transforming Growth Factor-beta1 (TGF-beta1) plays an important role in the biology of high-grade gliomas, partly by regulating invasion of these tumors into parenchyma. This study was designed to evaluate if TGF-beta1 induces the expression and deposition of Tenascin-C in the extracellular matrix of high-grade gliomas which may be pivotal for the invasion of these tumors into healthy parenchyma. METHODS: A series of 20 high-grade gliomas was stained immunohistochemically with Tenascin-C- and TGF-beta1- specific antibodies. Expression levels of both proteins were evaluated and correlated with each other, time to progression and molecular and morphological markers of invasion. A quantitative PCR assay was performed evaluating the induction of Tenascin-C mRNA by treatment with TGF-beta1 in vitro. RESULTS:Tenascin-C was expressed in 18 of 19 (95%) evaluable tumors, whereas 14 of 20 tumors (70%) expressed TGF-beta1 in a significant percentage of cells. Treatment with TGF-beta1 did induce the expression of Tenascin-C at the mRNA and protein level in vitro. The expression of Tenascin-C and TGF-beta1 did neighter statistically correlate with each other nor with time to progression. CONCLUSION: In our series, Tenascin-C and TGF-beta1 were expressed in the vast majority of high-grade gliomas. We could not detect a correlation of one of the proteins with time to progression. Nevertheless, we describe induction of Tenascin-C by TGF-beta1, possibly providing a mechanism for the invasion of high-grade gliomas into healthy parenchyma.
Authors: Christel Herold-Mende; Margareta M Mueller; Mario M Bonsanto; Horst Peter Schmitt; Stefan Kunze; Hans-Herbert Steiner Journal: Int J Cancer Date: 2002-03-20 Impact factor: 7.396
Authors: W Paulus; I Baur; C Huettner; B Schmausser; W Roggendorf; K H Schlingensiepen; W Brysch Journal: J Neuropathol Exp Neurol Date: 1995-03 Impact factor: 3.685
Authors: Falk Wehrhan; Franz Rödel; Gerhard G Grabenbauer; Kerstin Amann; Wolfgang Brückl; Stefan Schultze-Mosgau Journal: Radiother Oncol Date: 2004-09 Impact factor: 6.280
Authors: Mary Helen Barcellos-Hoff; Elizabeth W Newcomb; David Zagzag; Ashwatha Narayana Journal: Semin Radiat Oncol Date: 2009-07 Impact factor: 5.934
Authors: Song Nie; Mikel Gurrea; Jianhui Zhu; Smathorn Thakolwiboon; Jason A Heth; Karin M Muraszko; Xing Fan; David M Lubman Journal: J Proteome Res Date: 2014-12-12 Impact factor: 4.466
Authors: N Sumru Bayin; Lin Ma; Cheddhi Thomas; Rabaa Baitalmal; Akhila Sure; Kush Fansiwala; Mark Bustoros; John G Golfinos; Donato Pacione; Matija Snuderl; David Zagzag; Mary Helen Barcellos-Hoff; Dimitris Placantonakis Journal: Neoplasia Date: 2016-12 Impact factor: 5.715